Basaljel

Basaljel: Uses, Side Effects, and Dosage Guide

Introduction to Basaljel

Basaljel is an antacid medication containing aluminum carbonate (Al(OH)3) used to treat acid indigestion, heartburn, and excess phosphate in the blood. It provides relief from these symptoms by neutralizing stomach acid and binding to phosphate. Basaljel is available as a prescription medication in the form of 500mg capsules.

Chemical Composition and Structure

The chemical formula of Basaljel is CH8Al2O7, also known as aluminum carbonate or dihydroxyaluminum sodium carbonate. It has a molecular weight of 174.0953 g/mol. The compound consists of an aluminum cation (Al3 ) bonded to carbonate anions (CO32-) in a trigonal structure.

Drug Classification

Basaljel belongs to the class of antacid medications. Antacids neutralize stomach acid to provide relief from acid indigestion and heartburn. It is also classified as a armacology-toxicology-and-pharmaceutical-science/phosphate-binder” target=”_blank”>phosphate binder, which helps lower phosphate levels in the blood by binding to dietary phosphate in the gastrointestinal tract.

Uses and Applications

Basaljel has several uses and applications, including:

  • Prevention of kidney stones by reducing excess phosphate in the blood
  • Management of hyperphosphatemia (high blood phosphate levels) in patients with chronic kidney disease
  • Treatment of heartburn and acid indigestion symptoms

Mechanism of Action

Basaljel works by neutralizing stomach acid and binding to excess phosphate in the gastrointestinal tract. The aluminum ions (Al3 ) in Basaljel react with hydrochloric acid (HCl) in the stomach to form aluminum chloride (AlCl3) and water (H2O), reducing acidity. Additionally, the carbonate ions (CO32-) bind to phosphate ions (PO43-), forming an insoluble aluminum phosphate complex that is excreted in the feces, lowering blood phosphate levels.

Dosage Forms and Strengths

Basaljel is available as a capsule containing 500mg of aluminum carbonate. The capsules are two-toned, with a red body and white cap, and are imprinted with ” Basaljel 500 MG.” The oblong-shaped capsules are taken orally, typically with meals or as directed by a healthcare provider.

armacology”> armacokinetics/”>Ph armacokinetics and Ph armacodynamics

After oral administration, Basaljel is not systemically absorbed and acts locally in the gastrointestinal tract. The aluminum ions are minimally absorbed, while the carbonate ions dissociate and react with stomach acid. The majority of the drug is excreted unchanged in the feces. Basaljel’s local effect on stomach acid and phosphate binding occurs within 1-2 hours of administration.

Clinical Indications

Basaljel is indicated for the treatment of the following conditions:

  • Hyperphosphatemia in patients with chronic kidney disease on dialysis
  • Heartburn and acid indigestion
  • Prevention of kidney stones in patients with high urinary phosphate levels

Side Effects

Common side effects of Basaljel include:

Rare but severe side effects may include allergic reactions, intestinal obstruction, and aluminum toxicity, particularly in patients with impaired renal function. Patients should report any side effects to their healthcare provider.

Warnings and Precautions

Basaljel is contraindicated in patients with known hypersensitivity to aluminum-containing products. It should be used with caution in patients with renal impairment, as aluminum accumulation may lead to toxicity. Long-term use of Basaljel may result in aluminum absorption and bone toxicity. Patients should not exceed the recommended dosage and duration of treatment.

Drug Interactions

Basaljel may interact with several medications, including:

Patients should inform their healthcare provider about all medications they are taking before starting Basaljel therapy.

Patient Information

Patients should take Basaljel exactly as prescribed by their healthcare provider. The capsules should be swallowed whole with a glass of water, and should not be crushed, chewed, or opened. Basaljel is typically taken with meals or as directed. Patients should not take Basaljel for longer than recommended and should attend regular check-ups to monitor their kidney function and blood phosphate levels.

Commercial Availability

Basaljel is available by prescription under the brand name Basaljel and various generic formulations. It is manufactured and distributed by several ph armaceutical companies worldwide. Patients can obtain Basaljel from local ph armacies with a valid prescription from their healthcare provider.

Alternative Treatments

Other medications used to treat hyperphosphatemia and acid indigestion include:

  • Calcium-based phosphate binders (calcium carbonate, calcium acetate)
  • Sevelamer (Renagel)
  • Lanthanum carbonate (Fosrenol)
  • Magnesium-containing antacids ( Milk of Magnesia)
  • Proton pump inhibitors (omeprazole, lansoprazole)

The choice of treatment depends on the patient’s individual needs, medical history, and potential side effects.

Regulatory Status

Basaljel has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. It is a prescription medication and is not available over-the-counter. The safety and efficacy of Basaljel have been established through clinical trials and post-marketing surveillance.

Clinical Studies and Evidence

Several clinical studies have investigated the efficacy and safety of Basaljel in the management of hyperphosphatemia and acid indigestion. A randomized, double-blind, placebo-controlled trial demonstrated that Basaljel significantly reduced serum phosphate levels in patients with chronic kidney disease on hemodialysis. Another study showed that Basaljel was effective in relieving heartburn and acid indigestion symptoms compared to placebo.

armacy”> armacy/”>Ph armacy Guide

armacist/”>Ph armacists play a crucial role in educating patients about the proper use of Basaljel. They should provide the following counseling points:

  • Take Basaljel as prescribed, typically with meals or as directed
  • Swallow capsules whole; do not crush, chew, or open them
  • Report any side effects or concerns to the prescribing healthcare provider
  • Attend regular check-ups to monitor kidney function and blood phosphate levels
  • Store Basaljel at room temperature, away from moisture and heat

Patent and Intellectual Property

The original patent for Basaljel was filed by the ph armaceutical company Bieffe Chemical Co. in 1995. Since then, several patents have been granted for various formulations and manufacturing processes related to aluminum carbonate-based phosphate binders. The intellectual property rights for Basaljel are currently held by multiple ph armaceutical companies worldwide.

Literature and References

  1. Salusky, I. B., & Goodman, W. G. (2001). Aluminum Toxicity in Patients with Chronic Renal Failure. Advances in Renal Replacement Therapy, 8(1), 38-47. https://pubmed.ncbi.nlm.nih.gov/11211682/
  2. Sheikh, M. S., Maguire, J. A., Emmett, M., Santa Ana, C. A., Nicar, M. J., Schiller, L. R., & Fordtran, J. S. (1989). Reduction of Dietary Phosphorus Absorption by Phosphorus Binders: A Theoretical, In Vitro, and In Vivo Study. Journal of Clinical Investigation, 83(1), 66-73. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC303670/
  3. Weisberg, L. S., & Kurnik, B. R. (1998). Aluminum Toxicity in Chronic Renal Failure. Seminars in Dialysis, 11(3), 191-195. https://pubmed.ncbi.nlm.nih.gov/9633562/

Conclusion

Basaljel is an effective antacid medication used to manage hyperphosphatemia, heartburn, and acid indigestion. Its aluminum carbonate content neutralizes stomach acid and binds to dietary phosphate, providing symptomatic relief and lowering blood phosphate levels. While generally safe, Basaljel may cause side effects and interact with other medications. Patients should use Basaljel as directed by their healthcare provider and attend regular check-ups to monitor their response to treatment. Ongoing research continues to investigate the long-term safety and efficacy of Basaljel in various patient populations.

Basaljel